uPA Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride hydrochloride dihydrate | 17440-83-4 | sc-364401 | 250 mg | $77.00 | 1 | |
Inhibits uPA by directly interacting with its active site, leading to reduced proteolytic activity involved in tissue remodeling and invasion. | ||||||
uPA Inhibitor II, UK122 | 1186653-73-5 | sc-356185 | 5 mg | $360.00 | 5 | |
uPA Inhibitor II, UK122, is a selective inhibitor that interacts with the urokinase-type plasminogen activator (uPA) through specific binding to its active site. This compound exhibits unique conformational flexibility, allowing it to stabilize the enzyme in an inactive state. Its distinct molecular interactions, including hydrogen bonding and hydrophobic contacts, can significantly alter the kinetics of plasminogen activation, influencing proteolytic pathways and cellular signaling mechanisms. | ||||||
Amiloride • HCl | 2016-88-8 | sc-3578 sc-3578A | 25 mg 100 mg | $22.00 $56.00 | 6 | |
Amiloride • HCl acts as a potent uPA inhibitor by engaging in specific interactions with the enzyme's active site, effectively modulating its activity. The compound's unique structural features facilitate strong electrostatic interactions and hydrophobic stacking, which can lead to altered reaction kinetics. This modulation impacts the dynamics of proteolytic cascades, influencing various cellular processes and signaling pathways through its selective binding affinity. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
Amiloride exhibits unique characteristics as a uPA inhibitor, primarily through its ability to form stable complexes with the enzyme. Its distinct molecular architecture allows for precise alignment within the active site, enhancing binding affinity. The compound's hydrophilic regions promote solvation effects, while its aromatic moieties contribute to π-π interactions, influencing the overall stability of the enzyme-substrate complex. This interplay alters the kinetics of proteolytic activity, impacting downstream signaling mechanisms. | ||||||
1,5-Dansyl-Glu-Gly-Arg Chloromethyl Ketone, Dihydrochloride | sc-220558 | 5 mg | $462.00 | |||
1,5-Dansyl-Glu-Gly-Arg Chloromethyl Ketone, Dihydrochloride acts as a uPA inhibitor by engaging in specific interactions with the enzyme's active site. Its unique structure facilitates the formation of covalent bonds, leading to irreversible inhibition. The presence of dansyl groups enhances fluorescence properties, allowing for real-time monitoring of enzyme activity. Additionally, the compound's hydrophobic regions contribute to its membrane permeability, influencing cellular uptake and localization. | ||||||
N-alpha-Benzoyl-L-argininamide hydrochloride | 4299-03-0 | sc-301278 sc-301278A | 5 g 25 g | $93.00 $270.00 | ||
N-alpha-Benzoyl-L-argininamide hydrochloride functions as a uPA inhibitor through its ability to form stable complexes with the enzyme, disrupting its catalytic activity. The benzoyl moiety enhances hydrophobic interactions, promoting binding affinity. Its amide linkage contributes to conformational rigidity, influencing the kinetics of enzyme-substrate interactions. Furthermore, the compound's solubility characteristics facilitate its diffusion across biological membranes, impacting its distribution within cellular environments. | ||||||
GGACK | 65113-67-9 | sc-201314 sc-201314A sc-201314B | 5 mg 25 mg 100 mg | $315.00 $1375.00 $5000.00 | ||
GGACK acts as a uPA inhibitor by engaging in specific non-covalent interactions with the enzyme's active site, effectively hindering its proteolytic function. The unique structural features of GGACK allow for enhanced electrostatic interactions, which stabilize the enzyme-inhibitor complex. Additionally, its distinct steric properties influence the conformational dynamics of uPA, altering the reaction kinetics and potentially modulating downstream signaling pathways. The compound's solubility profile also plays a crucial role in its bioavailability and interaction with cellular components. | ||||||
uPA Inhibitor Inhibitor | 149732-36-5 | sc-356184 | 5 mg | $311.00 | 1 | |
uPA Inhibitor functions by selectively binding to the active site of uPA, disrupting its enzymatic activity through precise molecular interactions. Its unique conformation promotes strong hydrogen bonding and hydrophobic contacts, which stabilize the inhibitor-enzyme complex. This binding alters the enzyme's structural dynamics, affecting its catalytic efficiency and influencing the kinetics of substrate turnover. Furthermore, the inhibitor's physicochemical properties enhance its affinity for uPA, impacting its overall efficacy in modulating proteolytic processes. | ||||||
BC 11 hydrobromide | 443776-49-6 | sc-362712 sc-362712A | 10 mg 50 mg | $306.00 $1224.00 | ||
Specifically inhibits uPA activity, thereby impacting processes like cell migration and invasion associated with uPA. | ||||||
4-Chlorophenylguanidine hydrochloride | 14279-91-5 | sc-203474 | 100 mg | $250.00 | ||
4-Chlorophenylguanidine hydrochloride exhibits a distinctive mechanism of action as a uPA inhibitor by engaging in specific electrostatic interactions with the enzyme's active site. Its unique molecular structure facilitates the formation of a stable complex, effectively hindering substrate access. The compound's hydrophilic and lipophilic balance influences its solubility and distribution, while its kinetic profile reveals a competitive inhibition pattern, altering the enzyme's activity and impacting proteolytic pathways. | ||||||